# iRE-C (NCT04108481)

> Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer

No report yet. It can be ordered.

- Drugs tested: durvalumab plus yttrium-90 radioembolization
- Indication: microsatellite stable colorectal cancer with liver metastases

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04108481
- Phase: PHASE1
- Status: TERMINATED
- Sponsor: University of Iowa
- Conditions: Colorectal Cancer Metastatic; Colon Cancer; Metastatic Colorectal Cancer; Rectal Cancer; Liver Metastasis Colon Cancer; Colo-rectal Cancer; Colorectal Adenocarcinoma; Colorectal Neoplasms; Liver Metastases; Colorectal Carcinoma
- Interventions: Durvalumab; Yttrium-90 RadioEmbolization
- Enrollment: 5
- Primary outcome: Determine the maximum tolerated dose (MTD) of Yttrium-90 radioembolization combined with immunotherapy durvalumab to treat liver-predominant metastatic colorectal cancer (mCRC)

## Indexed commentary on iRE-C so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=ire-c-nct04108481